Compare Samsara Inc (IOT) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Samsara Inc vs Tango Therapeutics Inc. — how do they compare? Samsara Inc trades at $40.5 (market cap $24.17B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Samsara Inc is far larger — about 6.4× Tango Therapeutics Inc.'s market cap, and Samsara Inc is trading nearer its 52-week high, Tango Therapeutics Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Samsara Inc for 19 Days and Tango Therapeutics Inc. for 0 Days on average.
| IOT | TNGX | |
|---|---|---|
Market Cap | $24.17B | $3.75B |
Volume | 3,228,585 | 9,619,106 |
Sector | Technology | Health |
52-Week High | $45.22 | $32.90 |
52-Week Low | $24.25 | $7.50 |
Typical Hold Time | 19 Days | 0 Days |
Enterprise Value | $23.41B | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Samsara Inc. (IOT) trades at $41.27, down 0.84% today, with a bullish technical signal from moving averages and a consensus analyst price target of $51.15. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.20 versus $0.16 expected, and revenue growth of 30% year-over-year. Recent news highlights partnerships and product launches, including the Samsara MCP for AI integration and a rewards program for drivers.
The outlook is positive due to robust revenue growth, expanding large-customer base, and analyst optimism, but risks include high valuation multiples (P/E of 275.13) and cash flow pressures. Investment opportunity lies in continued execution and market share gains, while investors should monitor margin sustainability and competitive dynamics.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Samsara Inc
Samsara provides a connected operations cloud that uses IoT data to help businesses improve efficiency and safety. Its platform offers real-time visibility for fleet management, equipment monitoring, and industrial sites.
Read more on IOT →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
